To Assess the Efficacy of Early Introduction of a Combination of Low Dose Vasopressin Analogue in Addition to Noradrenaline as a Vasopressor in Patients of Cirrhosis With Septic Shock

• Status: Completed
• Trial end date: 2017-05-31
• Target enrollment: 0
• Participant gender: All

Summary

The consecutive patients admitted to Intensive care unit of Hepatology department of ILBS and full filling all the eligibility criteria will be enrolled in 1:1 ration by the process of randomization.- The study is an open level study. The investigators will strictly follow the randomization table to give therapy as per the intervention arm.

• Intervention:-the therapeutic intervention is vasopressor i.e. noradrenaline alone and terlipressin along with noradrenaline to maintain the MAP >65mm Hg.

• Intervention arm

• Arm (A) - Noradrenaline

• Arm (B) - Noradrenaline + low dose terlipressin

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Liver and Biliary Sciences, India
• Treatments: Arginine Vasopressin; Lypressin; Norepinephrine; Terlipressin; Vasoconstrictor Agents; Vasopressins

Criteria

Inclusion Criteria:

• 18-70 yr

• Cirrhosis with septic shock not responding to fluid resuscitation within 2 hrs.

Exclusion Criteria:

• ECG (ElectroCardiography)changes at presentation which exclude the use of vasopressin analouges

• Cardiac dysfunction ( valvular heart disease, coronary artery disease)

• Acute mesenteric ischemia (confirmed or suspected) or vasospastic diathesis (e.g. Reynaud's syndrome or related diseases).

• Pregnancy

• Acute GI bleed

• No Consent